whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives

Women are asking whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives.

They're hearing about a stream of lawsuits against these drugs.

Lawyers are targeting Yaz and Yasmin partly due to FDA warnings about the company not adequately disclosing risks in consumer ads.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote